![]() The product is packaged in a kit containing 1mg of freeze-dried (lyophilized) product in a 3 mL vial and a pre-filled diluent syringe. Glucagon Emergency Kit is used as an anti-hypoglycemic agent and a gastrointestinal motility inhibitor indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. Associated with the one product complaint, it was reported to Lilly that the involved patient experienced lack of drug effect and also reported subsequent seizures. Risk Statement: Severe hypoglycemia in patients with diabetes, if not reversed, can potentially cause adverse health consequences ranging from transient, minor complaints to neurological damage, seizures, and even death if not promptly treated. The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency. The firm’s investigation indicates that the liquid in this Glucagon vial could be related to the manufacturing process. ![]() Lilly is recalling lot D239382D to the patient level because of a product complaint reporting that the vial of Glucagon was in liquid form instead of the powder form. Its industry sports an average Forward P/E of 13.98, so we one might conclude that Eli Lilly is trading at a premium comparatively.Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial Diluent for Glucagon, 1 mL syringe), to the consumer/user level. ![]() Valuation is also important, so investors should note that Eli Lilly has a Forward P/E ratio of 37.16 right now. Eli Lilly is holding a Zacks Rank of #3 (Hold) right now. Over the past month, the Zacks Consensus EPS estimate has moved 3.43% higher. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. This model considers these estimate changes and provides a simple, actionable rating system. Investors can capitalize on this by using the Zacks Rank. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. These revisions help to show the ever-changing nature of near-term business trends. These totals would mark changes of +6.8% and +6.83%, respectively, from last year.Īny recent changes to analyst estimates for Eli Lilly should also be noted by investors. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $8.48 per share and revenue of $30.49 billion. Our most recent consensus estimate is calling for quarterly revenue of $6.71 billion, down 14.07% from the year-ago period. This would mark a year-over-year decline of 38.17%. In that report, analysts expect Eli Lilly to post earnings of $1.62 per share. Investors will be hoping for strength from Eli Lilly as it approaches its next earnings release. In that same time, the Medical sector lost 3.29%, while the S&P 500 lost 4.54%. Elsewhere, the Dow gained 1.17%, while the tech-heavy Nasdaq added 12.91%.Ĭoming into today, shares of the drugmaker had lost 4.73% in the past month. The stock lagged the S&P 500's daily gain of 1.62%. In the latest trading session, Eli Lilly (LLY) closed at $318.43, marking a +1.07% move from the previous day.
0 Comments
Leave a Reply. |